Ahsan Akram (Affiliate)
Imaging in Lung Cancer for treatment stratification
Research in a Nutshell
Lung Cancer remains the leading cause of cancer related death worldwide with an extremely poor 5-year survival. Recently, immunotherapy treatments have shown efficacy in refractory NCSLC, but only in a small proportion of patients with failure of therapy in the majority. My work focuses on a subtype of cancer associated fibroblasts (CAFs) which express fibroblast activation protein (FAP+CAFs) in the tumour microenvironment. There is growing pre-clinical evidence these cells are responsible for immunotherapy failure.
I will utilise primary lung cancer specimens to characterise the fibroblast populations and assess their phenotype and role in immunotherapy failure, alongside targeted pharmacotherapy in pre-clinical models. I will also develop imaging strategies, both whole body approaches with PET imaging and high resolution optical imaging to ultimately understand the stromal response in patients during therapy. I hope that in the future these novel translational imaging approaches have the potential to stratify patients for tailored cancer immunotherapy (+/-companion therapeutics).
I also welcome potential collaborations and students.
Research Programme: Fibroblast Activation Protein Expressing Cancer Associated Fibroblasts from Lung Cancer As Imaging Biomarkers For Immunotherapy Stratification.
|Ahsan Akram||Programme Leader|
Cancer Research Collaborations
- Professor Margaret Frame, University of Edinburgh
- Professor Kev Dhaliwal, University of Edinburgh
- Professor Mark Bradley, University of Edinburgh
Partners and Funders (current)
- Cancer Research UK (Clinician Scientist Fellowship, Dec 2017-Dec 2022.)
- Wellcome Trust
Optical imaging, Molecular imaging, Immunotherapy failure, stromal response in lung cancer
Novel in vivo optical imaging technologies, New PET tracers, Cancer immunotherapy stratification based on imaging parameters